Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Similar papers

Open access Sep 2026

Preclinical characterization of S095029, a novel clinical-stage Fc-attenuated NKG2A-blocking antibody for cancer immunotherapy

Results support the clinical development of S095029 in immuno-oncology-responsive tumour settings with adequate HLA-E expression and show that S095029 inhibited tumour growth by harnessing the anti-tumour activity of both NK and CD8+ T cells.

Maria C. Melander, Franziska Uhlenbrock, Anne Worsaae et al. · 0 citations
Open access Sep 2026

29 Engineering CD16-Enhanced Stem Cell–Derived Universal NKT Cells to Potentiate Anti-CD70 Therapy in Renal Cell Carcinoma

CD16HSC-NKT cells are established as a versatile and scalable cellular platform that synergizes with cusatuzumab to enhance therapeutic efficacy against RCC, and represent a promising approach to overcoming current limitations of monoclonal antibody therapy and advancing next-generation immunotherapies for solid tumors...

Yan-Ruide Li, Yi-Chen Zhu, Yu-Ning Chen et al. · 0 citations
Open access Aug 2026

IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting

Chimeric antigen receptor (CAR) therapies have shown great success in hematological malignancies but remain largely ineffective against solid tumors such as pancreatic ductal adenocarcinoma (PDAC). A key obstacle among various aspects, is the dense stromal barrier formed by cancer-associated fibroblasts (CAFs), providi...

Laura Gehrcken, J. Ott, Astrid Van Den Eynde et al. · 0 citations
Open access Sep 2026

Enhanced CD33 CAR-NK cells secreting anti-CD73scFv overcome adenosine-mediated immunosuppression and improve anti-AML efficacy

The CD33-CD73 dual-targeting CAR-NK platform synergistically targets AML cells and the adenosine-rich TME, exhibiting superior anti-leukemia efficacy and provides a translational blueprint for TME-targeted therapies in other cancers.

Lu Wang, S. Gong, Jun Wang et al. · 0 citations
Review Open access Aug 2026

Targeting immune checkpoint B7-H6 in cancer immunotherapy

Current findings position B7-H6 as a promising immuno-oncologic target at the intersection of immune surveillance, immune escape, and malignant progression, warranting continued investigation as a next-generation therapeutic axis in cancer immunotherapy.

Ziyi Yang, Qi Zhao · 0 citations
Open access Aug 2026

Paracetamol and Metformin Reduce NK-Cell Susceptibility in MCF-7 Breast Cancer Cells in Association with Enrichment of Immune-Evasive CD44+CD24− Stem-like Subpopulations

Natural Killer (NK) cell-mediated immunosurveillance is a cornerstone of anti-tumor defense, yet its efficacy can be compromised by common clinical medications. Paracetamol (APAP) and metformin (MET) are widely used for pain and metabolic management in cancer patients, but their unintended effects on the immune–tumor i...

N. Truong, Nhi-Thao Huynh, K. G. Trinh et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.